155 related articles for article (PubMed ID: 16336755)
21. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.
Wong SF
Clin Ther; 2005 Jun; 27(6):684-94. PubMed ID: 16117976
[TBL] [Abstract][Full Text] [Related]
22. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.
Tol J; Dijkstra JR; Klomp M; Teerenstra S; Dommerholt M; Vink-Börger ME; van Cleef PH; van Krieken JH; Punt CJ; Nagtegaal ID
Eur J Cancer; 2010 Jul; 46(11):1997-2009. PubMed ID: 20413299
[TBL] [Abstract][Full Text] [Related]
23. Epidermal growth factor receptor as a target for chemotherapy.
Vallbohmer D; Lenz HJ
Clin Colorectal Cancer; 2005 Apr; 5 Suppl 1():S19-27. PubMed ID: 15871762
[TBL] [Abstract][Full Text] [Related]
24. Cetuximab: from bench to bedside.
Vincenzi B; Zoccoli A; Pantano F; Venditti O; Galluzzo S
Curr Cancer Drug Targets; 2010 Feb; 10(1):80-95. PubMed ID: 20088790
[TBL] [Abstract][Full Text] [Related]
25. Current situation of Panitumumab, Matuzumab, Nimotuzumab and Zalutumumab.
Rivera F; Vega-Villegas ME; Lopez-Brea MF; Marquez R
Acta Oncol; 2008; 47(1):9-19. PubMed ID: 18097777
[TBL] [Abstract][Full Text] [Related]
26. Clinical use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer.
Patel DK
Pharmacotherapy; 2008 Nov; 28(11 Pt 2):31S-41S. PubMed ID: 18980550
[TBL] [Abstract][Full Text] [Related]
27. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.
Raben D; Helfrich B; Chan DC; Ciardiello F; Zhao L; Franklin W; Barón AE; Zeng C; Johnson TK; Bunn PA
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):795-805. PubMed ID: 15701870
[TBL] [Abstract][Full Text] [Related]
28. [Predictive biomarkers of anti-EGFR monoclonal anti-body in colorectal cancer].
Soeda H; Shimodaira H; Ishioka C
Gan To Kagaku Ryoho; 2011 Jul; 38(7):1079-83. PubMed ID: 21772090
[TBL] [Abstract][Full Text] [Related]
29. Monoclonal antibodies targeting epidermal growth factor receptor and vascular endothelial growth factor with a focus on head and neck tumors.
Caponigro F; Formato R; Caraglia M; Normanno N; Iaffaioli RV
Curr Opin Oncol; 2005 May; 17(3):212-7. PubMed ID: 15818163
[TBL] [Abstract][Full Text] [Related]
30. Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study.
Shia J; Klimstra DS; Li AR; Qin J; Saltz L; Teruya-Feldstein J; Akram M; Chung KY; Yao D; Paty PB; Gerald W; Chen B
Mod Pathol; 2005 Oct; 18(10):1350-6. PubMed ID: 15832190
[TBL] [Abstract][Full Text] [Related]
31. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
Jean GW; Shah SR
Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
[TBL] [Abstract][Full Text] [Related]
32. Assessment of epidermal growth factor receptor with 99mTc-ethylenedicysteine-C225 monoclonal antibody.
Schechter NR; Yang DJ; Azhdarinia A; Kohanim S; Wendt R; Oh CS; Hu M; Yu DF; Bryant J; Ang KK; Forster KM; Kim EE; Podoloff DA
Anticancer Drugs; 2003 Jan; 14(1):49-56. PubMed ID: 12544258
[TBL] [Abstract][Full Text] [Related]
33. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer.
Khambata-Ford S; Harbison CT; Hart LL; Awad M; Xu LA; Horak CE; Dakhil S; Hermann RC; Lynch TJ; Weber MR
J Clin Oncol; 2010 Feb; 28(6):918-27. PubMed ID: 20100958
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer.
Ready N
Semin Oncol; 2005 Apr; 32(2 Suppl 3):S35-41. PubMed ID: 16015534
[TBL] [Abstract][Full Text] [Related]
35. Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment.
Capdevila J; Elez E; Macarulla T; Ramos FJ; Ruiz-Echarri M; Tabernero J
Cancer Treat Rev; 2009 Jun; 35(4):354-63. PubMed ID: 19269105
[TBL] [Abstract][Full Text] [Related]
36. Recent data with anti-epidermal growth factor receptor antibodies and irinotecan in colon cancer.
Chua YJ; Cunningham D
Clin Colorectal Cancer; 2005 Nov; 5 Suppl 2():S81-8. PubMed ID: 16336753
[TBL] [Abstract][Full Text] [Related]
37. Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients.
Montagut C; Iglesias M; Arumi M; Bellosillo B; Gallen M; Martinez-Fernandez A; Martinez-Aviles L; Cañadas I; Dalmases A; Moragon E; Lema L; Serrano S; Rovira A; Rojo F; Bellmunt J; Albanell J
Br J Cancer; 2010 Mar; 102(7):1137-44. PubMed ID: 20234366
[TBL] [Abstract][Full Text] [Related]
38. Combined assessment of epidermal [corrected] growth factor receptor dual color in situ hybridization and immunohistochemistry with downstream gene mutations in prediction of response to the anti-EGFR therapy for patients with metastatic colorectal cancer.
Takahashi N; Yamada Y; Taniguchi H; Honma Y; Iwasa S; Kato K; Hamaguchi T; Shimada Y
Arch Med Res; 2014 Jul; 45(5):366-74. PubMed ID: 24830936
[TBL] [Abstract][Full Text] [Related]
39. Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer.
Hebbar M; Wacrenier A; Desauw C; Romano O; Cattan S; Triboulet JP; Pruvot FR
Anticancer Drugs; 2006 Aug; 17(7):855-7. PubMed ID: 16926635
[TBL] [Abstract][Full Text] [Related]
40. Epidermal growth factor receptor biology (IMC-C225).
Kim ES; Khuri FR; Herbst RS
Curr Opin Oncol; 2001 Nov; 13(6):506-13. PubMed ID: 11673692
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
